Shots:
IMPACT Therapeutics has entered into an exclusive licensing agreement with Pharmanovia for the exclusive rights to manufacture, develop, and commercialise senaparib in EMEA, Australia, and New Zealand
As per the deal, Pharmanovia will acquire exclusive rights to manufacture, develop & commercialise senaparib across EMEA, Australia & New Zealand, with IMPACT eligible for upfront, regulatory…
Shots:
Pharmanovia has signed an exclusive in-licensing agreement with Radius Health for abaloparatide (US brand name: Tymlos) to treat osteoporosis, expanding its osteoporosis franchise
Pharmanovia will handle clinical, regulatory & commercial responsibilities across APAC region (China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau & Philippines), while Radius will get an upfront, regulatory…

